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Abstract: The total body weight-based dosing strategy currently used in the prophylactic treatment of
hemophilia A may not be appropriate for all populations. The assumptions that guide weight-based
dosing are not valid in overweight and obese populations, resulting in overdosing and ineffective
resource utilization. We explored different weight metrics including lean body weight, ideal
body weight, and adjusted body weight to determine an alternative dosing strategy that is both
safe and resource-efficient in normal and overweight/obese adult patients. Using a validated
population pharmacokinetic model, we simulated a variety of dosing regimens using different
doses, weight metrics, and frequencies; we also investigated the implications of assuming various
levels of endogenous factor production. Ideal body weight performed the best across all of the
regimens explored, maintaining safety while moderating resource consumption for overweight and
obese patients.
Keywords: hemophilia A; conventional factor VIII; dose metrics; obesity;
population pharmacokinetics
1. Introduction
Hemophilia A is an inherited bleeding disorder resulting from a deficiency in clotting factor
VIII (FVIII), causing spontaneous and recurring joint bleeds, eventually leading to arthropathy and
premature death if left untreated. The mainstay of severe hemophilia treatment is prophylactic
replacement of the missing factor. The typical aim of prophylaxis is to maintain a clotting factor
level of at least 1 IU dL−1, based on the observation that patients with moderate hemophilia (i.e.,
those with baseline factor levels >1 IU dL−1) are less prone to the spontaneous bleeds and subsequent
arthropathy seen in more severe cases [1]. In a study of 65 boys with severe hemophilia A, only
regular prophylactic infusions were shown to prevent joint damage as compared to on-demand
treatment [2]. While there is global unanimity that prophylaxis should be initiated before joint disease
is sustained [3,4], the implementation of this approach is quite variable [5]. No optimal dosing regimen
has been identified; instead, an individualized approach that accounts for the patient’s physical activity,
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current (and accepted future) musculoskeletal condition, and the availability of resources has been
suggested [6,7]. Ideally, the patient’s pharmacokinetic (PK) profile is taken into account to define a
truly individualized regimen that optimizes both safety and resource utilization [8]. To facilitate the
adoption of PK-based dosing regimens, tools such as the Web Accessible Population Pharmacokinetics
Service—Hemophilia (WAPPS-Hemo [9,10]) provide estimates of individual PK parameters from a
minimal number of samples by leveraging population PK data. Despite the development of these
platforms, the majority of hemophilia patients are still dosed according to total body weight, as
initially proposed by Ingram in 1981 [11]. For instance, hemophilic children in Canada are started on
a once-weekly regimen (50 IU kg−1), then step up to either twice weekly (30 IU kg−1) or every 48 h
(25 IU kg−1) as required; prophylaxis regimens in the Netherlands (Utrecht protocol: 15–30 IU kg−1
three times per week) and Sweden (Malmö protocol: 25–40 IU kg−1 three times per week), though
proposing different intensities and targeting different levels, are based on the same principle [12].
The normalization of life expectancy of individuals with hemophilia brings new challenges to
hemophilia care. Overweight and obesity rates amongst hemophiliacs now match the epidemic
proportions that are seen in the general population [13]. A 2011 study conducted in Ontario found
28.8% of enrolled hemophiliacs were overweight or obese, compared to 26% of healthy controls [14].
Obesity also comes with a higher risk for hemophilic arthropathy; joint range of motion has been shown
to negatively correlate with body mass index (BMI) [15]. Furthermore, the total body weight-based
dosing regimen currently used in hemophilia treatment may not be appropriate for overweight and
obese populations. Calculations for weight-adjusted dosing are based on the following formula:
Dose (IU) =
total body weight (kg)× desired increase in FVIII level (%)
IVR
(1)
In vivo recovery (IVR) is a parameter used to describe clotting factor pharmacokinetics, and
reflects the rise in factor activity (in this case, FVIII) after a dose is administered. Although it has been
suggested that an individual IVR value be determined for each patient [16], typically an IVR of 2 IU
dL−1/IU kg−1 is assumed. For example, a desired increase to normal FVIII levels (100%) would lead
to a 50 IU kg−1 dose being administered. However, the assumption that IVR equals 2 for all is not
always valid. A study by Henrard et al. found that overweight patients (BMI > 29.6 kg·m−2) had a
median IVR of 2.70, while underweight patients (BMI < 20.3 kg·m−2) had a median IVR of 1.60 [17].
The emerging proportion of overweight and obesity in the general population has prompted
research efforts aimed at identifying pharmacokinetic differences (and the corresponding dose
adjustments) in this population. The relationship between body size and clearance is well established;
a 2012 systematic review of this topic found that more than half of all identified models for clearance
included a covariate for body size, most commonly as a power function [18]. Obesity specifically
influences several factors affecting drug disposition, including body composition, metabolism by
CYP450 enzymes, and plasma protein levels [19]. The most striking differences are observed for highly
lipophilic drugs, where volume of distribution changes dramatically in the obese population [20].
However, this is not the case for clotting factor concentrates. FVIII concentrates are typically confined
to the vascular space, with volumes of distribution approximating plasma volume (48 mL·kg−1) [21].
Since vasculature represents a very small fraction (0.005–0.010) of adipose tissue volume [22], an
excess (or scarcity) of fat does not significantly alter the volume of distribution of FVIII. As a
result, overweight and obese patients are likely overdosed when dose is calculated using total body
weight [23]. A similar issue has been noted for dosing of unfractionated heparin, another compound
whose volume of distribution is approximately equal to the plasma volume; obese children achieved
comparable anticoagulation at a lower weight-based dose [24]. Hemophilia treatment is expensive,
with annual costs in the hundreds of thousands for those on prophylaxis [2], and while prophylaxis
does achieve better health outcomes, these come at a significant cost that is not automatically offset
by prevention of other expenses [25]. As the clotting factor itself represents the majority of the cost
of prophylaxis [26], overdosing can introduce a significant waste of resources [27]. This study will
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explore alternative dosing regimens that optimize both safety and resource utilization in overweight
and obese hemophiliacs.
2. Methods
Population generation, simulation, and data analysis were all conducted in Matlab R2009.
2.1. Population Generation
The generated population of virtual individuals consists of two equal sized bins classified by BMI
using the cut-offs defined by Henrard et al. [17] The first group consists of average weight subjects
(BMI between 20.3 and 29.6 kg·m−2); the second group represents an overweight and obese population
with BMI between 29.6 kg·m−2 and 40.0 kg·m−2. These cut-off values for BMI were found to be the
strongest predictors of FVIII IVR. Each group contains 1000 simulated subjects with a uniform BMI
distribution. Heights were derived from the distribution provided by the NHANES database [28].
A uniform distribution of BMI’s was simulated and the total body weights were calculated as the
product of BMI and the square of height.
2.2. Definitions of Weight Metrics
The following weight metrics were defined for each virtual patient from their simulated total
body weight (TBW, kg), height (HT, cm) and BMI (kg·m−2):
1. Lean body weight (LBW) [29]
LBW =
9270 × TBW
6680 + 216 × BMI, (2)
2. Ideal body weight (IBW—Lorentz formula)






3. Adjusted body weight (ABW)
ABW25 = IBW + 0.25 × (TBW − BW), (4)
ABW40 = IBW + 0.4 × (TBW − IBW). (5)
We used the semi-mechanistic model for LBW developed by Janmahasatian et al. [30] as it has
been found to better describe the full range of adult heights and weights [20]. IBW was calculated
using Lorentz’s formula, which takes into account the patient’s height and sex but not total body
weight. ABW was the first weight metric intended for use in pharmacokinetic studies; it involves
adding a proportion of the excess weight above IBW [30]. This proportion is variable, ranging from
25–50%, with 40% being used most commonly; in this study, we examined both 25% (ABW25) and 40%
(ABW40) correction factors. Correlation plots for all body size metrics are presented in Supplementary
Figures S1 and S2 for normal and overweight/obese individuals, respectively.
2.3. Population Pharmacokinetic Model
Simulations were performed using the 2-compartment structure described by Garmann et al. [31]
for BAY 81-8973 (Kovaltry®, Bayer, Leverkusen, Germany), built on 183 subjects. Of the 109 patients
above 18 years of age, the BMI range was 15.0–38.3 kg·m−2. The details of the model structure are
presented in Table 1. For each simulated individual, PK parameters were calculated. Each virtual
individual was then dosed based on various weight metrics and their PK was simulated.
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Table 1. Details of the model developed by Garmann et al. [31]. CL: clearance; Q: intercompartmental
clearance; V1: volume of the central compartment; V2: volume of the peripheral compartment; RUV:
residual unexplained variability; BSV: between subject variability; LBW: lean body weight.
Parameter Estimate Covariate Effect BSV (%CV)














Proportional RUV (%CV) 26.7
Additive RUV (IU dL−1) 1.10
2.4. Simulation and Assessment of Treatment Regimens
For each virtual individual, FVIII levels and individual PK parameters were simulated assuming
a baseline factor level of 0.5 IU dL−1. FVIII levels were simulated using time steps of 0.2 h following
dosing regimens for four weeks to ensure that steady state was reached, and results from the 5th week
were used in subsequent analysis steps. In a first instance, we analyzed a typical dosing strategy
(20 IU kg−1 TBW every 48 h) to evaluate its appropriateness.
We then simulated various regimens wherein equal doses were given at regular intervals (i.e., 48 h).
Each patient was dosed from 10 IU kg−1 for each weight metric (10 IU kg−1 of TBW, 10 IU kg−1 of
LBW, etc.) up to 210 IU kg−1. Initially, the dose step was 2 IU kg−1 for doses up to 100 IU kg−1 and
10 IU kg−1 for doses between 100 and 210 IU kg−1. After reviewing the results, the dose step was
reduced to 0.1 IU kg−1 between 20 and 30 IU kg−1, as this was the range of most interest. A regimen
was considered to be safe for a BMI group if 95% of the simulated population within that group had
factor levels above 1 IU dL−1 at all times (Cmin ≥ 1 IU dL−1). The lowest dose per weight metric that
met this safety criterion was identified and considered to be the optimal regimen for that particular
metric and BMI group. A secondary measure of safety was the 95th quantile for time spent below 1 IU
dL−1; in other words, the amount of time per week spent below trough for the 5% of the population
not meeting the safety criteria. To evaluate economic differences between regimens, we calculated
the mean weekly consumption on each optimal regimen to determine which dosing regimen met
safety requirements while minimizing resource expenditure. This process was then repeated for a
Monday-Wednesday-Friday (M-W-F) dosing schedule. For these simulations, the optimal dose for
each metric (determined in the previous simulations) was administered on Monday and Wednesday,
and the Friday dose was increased until the safety criterion was reached. To evaluate the importance of
the earlier assumption of 0.5 IU dL−1 baseline, we repeated the above simulations assuming a baseline
of 0 IU dL−1 to observe if similar trends emerged.
3. Results
Simulations of the typical regimen of 20 IU kg−1 TBW every 48 h were completed and the results
are summarized in Table 2. We then investigated the hypothesis that a TBW-based dosing regimen
results in overdosing in overweight and obese patients by determining the TBW-based dose required to
meet the 1 IU dL−1 safety criterion in 95% of these patients. At a dose of 20 IU kg−1 TBW, the median
minimum concentration (Cmin) throughout the week for these patients was 5.4 IU dL−1; the average
consumption associated with this dosing regimen was 7.25 × 103 IU per person per week. However,
this population requires only 14 IU kg−1 TBW to meet the 95% safety criterion, which corresponds to
an average weekly consumption of 5.07 × 103 IU per person.
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Table 2. Comparison of the typical 20 IU kg−1 total body weight (TBW) dose and the lowest dose
meeting the safety threshold (i.e., 14 IU kg−1 TBW) in overweight and obese patients. Results are
presented as median (90% confidence interval).
Measure
Regimen
20 IU kg−1 TBW, Q48 h 14 IU kg−1 TBW, Q48 h
Cmin (IU dL−1) 5.4 (1.2–17.3) 3.9 (1.0–12.3)
Consumption (IU per person per week) 7260 (5730–8780) 5080 (4010–6140)
Following this initial investigation, we explored dosing regimens using alternative weight metrics.
The correlation between each weight metric and BMI is shown in Figure 1. We began by administering
a dose of 10 IU kg−1 of each weight metric on a Q48 h dosing schedule. Once steady state was reached,
the percentage of patients with Cmin ≥ 1.0 IU dL−1 was calculated. If this percentage was below 95%,
the dose was incrementally increased until this threshold was reached. We then calculated the mean
weekly consumption associated with the minimum dose required to reach the safety criterion for each
metric to assess cost-effectiveness. Since a Monday-Wednesday-Friday dosing schedule is commonly
used in hemophilia A prophylaxis, we performed analogous simulations using this schedule instead
of a regular 48 h interval. We used the optimal doses found in the previous study on Monday and
Wednesday, and then increased the dose on Fridays to compensate for the longer interval until the
safety criterion was met.
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Tables 3 and 4 summarize the doses per kg of each weight metric required to reach the 95% safety
criterion (when infused every 48 h or Monday-Wednesday-Friday, respectively) and the associated
weekly consumption in each of the BMI categories and in the merged population, assuming a baseline
factor level of 0.5 IU dL−1. The most appropriate regimen is the one that meets the safety requirements
while consuming the least amount of factor concentrate. For patients within the normal BMI range,
LBW produced the optimal regimen for both dosing schedules; for the overweight and obese cohort,
an IBW-based dosing regimen was found to be most cost-effective. Furthermore, the range of mean
weekly consumption across the various weight metrics was much tighter for the normal BMI subgroup
(125 IU per person per week) as compared to the overweight/obese subgroup (483 IU per person per
week). When the two subgroups were combined, ABW with a 25% correction factor proved to be ideal
for the Q48 h regimen, with IBW a very close second with a difference of just 5 IU per person per
week. Both ABW25 and IBW perform almost identically in terms of safety for both BMI subgroups for
the Q48 h regimen (Figure 2). However, IBW performed better than all other weight metrics when a
Monday-Wednesday-Friday schedule was adopted, with a difference in consumption of over 100 IU
per person per week when compared to the next best metric (LBW). Nevertheless, the amount of time
spent below 1 IU dL−1 is significantly greater when following a Monday-Wednesday-Friday regimen
as compared to the Q48 h dosing schedule (Figure 3b); additionally, an extremely high Friday dose
(>125 IU kg−1 TBW) is required to meet the 95% safety requirement, whereas a dose of 18 IU kg−1
TBW is successful for the Q48 h regimen (Figure 3a).
Table 3. Summary of safety and economic evaluations of different weight metrics used in a Q48 h
regimen across BMI subgroups, assuming a baseline factor level of 0.5 IU dL−1. Dose is the dose
required to have 95% of patients with a steady state Cmin over 1 IU dL−1. Optimal regimens for each
subgroup and the overall population are bolded. IBW: ideal body weight, ABW: adjusted body weight.
Metric




















TBW 20.0 5202 14.0 5074 18.0 5603 -
LBW 25.6 5114 21.3 5028 23.8 5186 −417
IBW 22.2 5222 20.7 4828 22.1 5176 −427
ABW25 21.7 5239 20.0 5311 20.4 5171 −432
ABW40 21.1 5173 18.0 5129 20.0 5301 −302
Table 4. Summary of safety and economic evaluations of different weight metrics used in a
Monday-Wednesday-Friday regimen across BMI subgroups, assuming a baseline factor level of 0.5
IU dL−1. Dose is the Friday dose required to have 90% of patients with a weekly Cmin ≥ 1 IU dL−1.
Optimal regimens for each subgroup and the overall population are bolded.
Metric


















TBW 74 8174 54 9320 62 8716 -
LBW 94 8082 82 8740 88 8442 −274
IBW 78 8213 84 8543 80 8312 −404
ABW25 78 8195 72 8558 76 8459 −258
ABW40 76 8126 68 8792 72 8481 −235
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1 IU dL−1 (hours per week) for TB -based dosing regimen administered at different intervals for the
combined group (normal + overweight/obese) for both Q48 h (blue) and Monday-Wednesday-Friday
(red) dosing schedules. For the Q48 h regimen, all doses are increasing along the X-axis; for the
Monday-Wednesday-Friday schedule, only the Friday dose is changing (Monday and Wednesday
doses are fixed at 20 IU per kg TBW).
Ideal body weight continued to perform well in simulations with an assumed baseline of 0 IU
dL−1. The safety ratio versus dose curves are once again nearly identical for both BMI subgroups
(Figure 4), although consumption was approximately doubled as compared to the Q48 h regimen.
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for a Q48 h regimen. Safety (%) is the percentage of patients with Cmin ≥ 1 IU dL−1 at various doses
per kg of IBW.
4. iscussion
e began by assessing the safety and cost-effectiveness of a typical 20 IU kg−1 TBW, Q48 h regimen
in an overweight and obese patient population. For comparison, we determined the TBW-based dose
required to meet the safety criterion. At a dose of 14 IU kg−1 TBW, 95% of patients had FVIII levels of at
least 1 IU dL−1 at all times; the median Cmin was 3.9 IU dL−1 and the mean consumption was just over
5000 IU per person per week. By contrast, the 20 IU kg−1 TBW regimen produced a median Cmin of
5.4 IU dL−1 with a mean consumption of 7250 IU per person per week. Hence, the standard TBW-based
dosing protocol results in over 40% higher consumption than required in the overweight and obese
population; assuming a cost of $1 US per unit of concentrate, this amounts to over $100,000 US in
excess spending per person annually. From this evaluation, it is clear that TBW does not represent the
optimal body weight metric to guide FVIII dosing.
Simulations using dosing regimens based on alternative weight metrics (LBW, IBW, ABW25,
and ABW40) were carried out using the two most common dosing schedules in hemophilia A
prophylaxis: a regular 48 h regimen and a Monday-Wednesday-Friday regimen. Adapting a
Monday-Wednesday-Friday timetable made it extremely difficult to meet the safety requirement,
regardless of which weight metric was used to define the dose. While patients are often advised
to increase their FVIII dose on Friday, a simple doubling of the dose is not sufficient. A potentially
harmful Friday dose of 140 IU kg−1 TBW was required for 95% of patients to have a Cmin ≥ 1 IU dL−1,
compared to 18 IU kg−1 TBW to meet this safety minimum when infused every 48 h. Furthermore, the
time spent below 1 IU dL−1 (and, consequently, the risk of bleeding events [32]) is significantly greater
when following a Monday-Wednesday-Friday regimen, even if the Friday dose is twice or three times
greater than the Monday and Wednesday doses (Figure 3b). In fact, a 2010 study in which FVIII was
administered three times per week found that over 80% of bleeds occurred 48–72 h post-infusion [33].
The Monday-Wednesday-Friday treatment schedule, while more convenient, is no longer considered
to be optimal therapy due to this increased vulnerability to bleeds during the weekend, with alternate
day dosing representing the ideal regimen [34,35].
Due to analytical limitations, it can be difficult to obtain an exact measure of a patient’s baseline
factor level. Many assays have a lower limit of quantification of 1 IU dL−1 [36,37], which is greater
than endogenous levels for severe hemophilia patients. To balance both safety and resource utilization,
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we ran initial simulations with an assumed baseline of 0.5 IU dL−1. However, it is known that many
severe hemophilia patients possess a genetic mutation such that no functional FVIII is produced
endogenously. For this reason, the simulations were performed again using a baseline of 0 IU dL−1
to ensure similar trends were observed within this sub-population. Notably, a 95% safe ratio can be
achieved in a population with no endogenous FVIII production at a reasonable dose (34 IU kg−1 TBW)
if administered every 48 h. However, it is not possible to meet that safety threshold in this population
if a Monday-Wednesday-Friday dosing schedule is employed. If the safety criteria is lowered to 90%,
it can be met, but only with extremely high Friday doses (between 130 and 180 IU kg−1 for the various
weight metrics) and associated weekly consumption (>16,000 IU per person per week); a study by
Collins et al. found similarly high doses (>100 IU kg−1 for patients with average half-lives, and up to
400 IU kg−1 in extreme cases) were required to maintain FVIII levels above 1 IU dL−1 throughout the
week when following this dosing schedule [38]. These results suggest that a regular dosing interval of
48 h offers significant advantages over the weekly Monday-Wednesday-Friday schedule in terms of
both safety and cost-effectiveness.
After exploring all combinations of dosing schedule and baseline factor level, we determined that
IBW-based dosing provides a safe and cost-effective regimen in the majority of scenarios, with ABW25
producing fairly similar results. Ideal body weight performed almost exactly the same in terms of
safety between the normal and overweight groups across all of the doses and regardless of baseline,
as evidenced by the closeness of the curves shown in Figures 2 and 4. Further, IBW was the most
cost-effective in three out of four simulations; in the fourth, it differed by only 5 IU per person per
week from the optimal regimen (ABW25). If we compare the optimal regimen for a Q48 h schedule
with a baseline of 0.5 IU dL−1 (i.e., 20.7 IU kg−1 IBW) to a 20 IU kg−1 TBW, this alterative regimen
offers a savings of over 2000 IU per person per week (or nearly $110,000 US annually) for overweight
and obese patients. Thus, IBW-based dosing offers a similar safety profile to the currently used TBW
strategy while moderating the economic burden of clotting factor prophylaxis.
This exercise was limited by the constraints of the data. The model used herein was built on
PK data from a specific brand of FVIII concentrate, although brand has not generally been found to
significantly influence PK. A second limitation to the applicability of this approach is that the source
data is largely from older (10+ years of age) patients, and the opinions on use of prophylaxis in adults
are varied [39–41]. Obesity rates are also increasing rapidly amongst pediatric patients and similar
dosing adjustments are likely appropriate in this population, but cannot be confirmed in this study.
Further study of pediatric populations (and validated pediatric population PK models) is required in
order to determine a dosing regimen that applies not only to all BMI’s but also to all ages.
As the prevalence of obesity has risen in the general population, a number of studies have
been conducted to investigate the frequency of overweight and obesity among hemophilia patients,
complications such as co-morbidities and decreased quality of life, and recommendations for
management strategies. Many pharmacokinetic studies exploring the relationship between excess
body weight and plasma volume (and, by extension, in vivo recovery) have postulated that dosing
according to body weight results in overdosing and an ineffective use of resources, suggesting instead
that dosing be guided by LBW or IBW [42,43]. This study compared several weight metrics and
confirmed that an IBW-based regimen is both safe and cost-effective across a range of BMI’s. Ideal
body weight produced slightly better results than other weight metrics because it is calculated based
solely on height; as shown in Figure 1, there is no correlation between IBW and BMI as observed with
the other metrics investigated.
Although we were able to identify a weight metric that is more suitable for a variable population,
the high inter-individual variability in PK handling of factor concentrates precludes the definition of a
single, “one dose fits all” strategy. In order to optimize prophylaxis, regimens should be tailored to
the individual PK profile. This process has been facilitated by the development of the WAPPS-Hemo
service (www.wapps-hemo.org), a Canadian-based user-friendly and industry-independent platform
that produces estimates of individual PK parameters through a Bayesian iterative approach.
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The WAPPS-Hemo service also includes a module for dosing regimen development, wherein clinicians
can predict the effects of changing dose, frequency, or targeted trough for a specific patient before
implementing these changes in practice. While PK-tailored dosing regimens may offer the best results,
weight-based strategies are still the norm, but these can be optimized by adapting a different weight
metric (i.e., IBW) to guide safe and cost-effective dosing at a population level.
5. Conclusions
In summary, we conducted simulations based on a previously published model of a conventional
FVIII to explore the appropriateness of different weight metric-based dosing regimens for hemophilia
A prophylaxis for overweight and obese patients. Regimens were required to produce a Cmin ≥ 1 IU
dL−1 in 95% of the population, and then the average consumption for each regimen was calculated to
evaluate resource-effectiveness. From this study, we conclude that ideal body weight performs the
best, maintaining safety while tempering factor consumption for overweight and obese patients.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4923/9/4/47/s1,
Figure S1: Correlation plots for all body size metrics used in simulations for the normal BMI subgroup. Diagonal
elements contain histograms. Figure S2: Correlation plots for all body size metrics used in simulations for the
overweight/obese subgroup. Diagonal elements contain histograms.
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